Clinical Trials · NCT04883606
A Study With Teduglutide (Revestive®) in Adults With Short Bowl Syndrome
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Takeda
- Enrollment
- 65
- Start date
- Jan 2022
- Locations
- 1 site, Spain
- Primary endpoint
- Percentage of Participants Achieving Response of 20 Percent (%) to 100% Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Month 1